Extended Data Fig. 6: Exploratory analysis of OS in subgroups defined by the F1L CDx assay OS survival curves for the bTMB ≥13.6 mut/Mb population atezolizumab arm vs chemotherapy arm and OS HRs at various bTMB cutoffs. | Nature Medicine

Extended Data Fig. 6: Exploratory analysis of OS in subgroups defined by the F1L CDx assay OS survival curves for the bTMB ≥13.6 mut/Mb population atezolizumab arm vs chemotherapy arm and OS HRs at various bTMB cutoffs.

From: Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Extended Data Fig. 6

Exploratory analysis of OS in subgroups defined by the F1L CDx assay (A) OS survival curves for the bTMB ≥13.6 mut/Mb population atezolizumab arm vs chemotherapy arm. Statistical analysis used a stratified log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. (B) Forest plot of OS HRs at various bTMB cutoffs. Atezo, atezolizumab; bTMB, blood-based tumor mutational burden; Chemo, chemotherapy; F1L CDx, FoundationOne Liquid Companion Diagnostic assay; HR, hazard ratio; OS, overall survival; PFS, progression-free survival. P values are descriptive.

Back to article page